<p><b>Evangelos Terpos</b>, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.</p>

Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.

Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!

Share Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

Sign up to save your podcasts

Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

More shows like Oncology Times - OncTimes Talk

Breast Cancer Trials